.jpeg)
2026-08-19 06:59:25
Tivozanib is an oral VEGFR tyrosine kinase inhibitor used in advanced renal cell carcinoma, administered at 1.34 mg once daily in a 21-days-on, 7-days-off, 28-day cycle. This article covers standard dosing, dose modification for adverse events, and reduced dosing for moderate hepatic impairment.
2026-08-19 04:40:21
Vemurafenib is an oral small-molecule BRAF kinase inhibitor designed to selectively target BRAF V600E and related mutations. This article explores its molecular mechanism, the essential role of BRAF genetic testing, and its positioning within precision oncology.
2026-08-17 06:12:53
Sotorasib (brand name: Lumakras), developed by Amgen, is the world's first KRAS G12C inhibitor approved by the U.S. FDA in May 2021. It is indicated for adults with KRAS G12C-mutant advanced non-small cell lung cancer and metastatic colorectal cancer.
2026-08-14 03:20:41
This article systematically interprets Osimertinib, a core therapeutic drug for EGFR mutation-positive non-small cell lung cancer, covering pharmacological efficacy, common and serious adverse reactions, indications, usage and dosage, drug interactions and key points for special populations, providing a comprehensive reference for standardized clinical medication.
2026-08-14 02:50:16
Sotorasib (brand name Lumakras) is the world's first approved targeted drug for KRAS G12C mutations, used in precision treatment of non-small cell lung cancer and colorectal cancer. This article explains its efficacy limits, approved indications, mechanism of action, and safety considerations to help patients set realistic treatment expectations.
2026-08-13 04:17:25
Trametinib is a highly selective MEK1/2 inhibitor used in BRAF V600-mutant melanoma, NSCLC, low-grade glioma, and other solid tumors. This article details refrigeration requirements, fasting dosing protocols, missed-dose management, eligible patient populations, and special-population considerations to support safe and standardized treatment.
2026-08-13 03:58:16
Belzutifan (brand name Welireg) is the first oral hypoxia-inducible factor-2α (HIF-2α) inhibitor, holding a unique position in managing VHL disease-associated tumors and clear cell renal cell carcinoma. This article systematically reviews its phased treatment strategy, survival outcomes, efficacy-modifying factors, adverse event management, and special-population considerations.
2026-08-12 04:21:50
Pemigatinib and Anlotinib are both anti-tumor targeted agents, yet they differ fundamentally in mechanism, target specificity, and applicable cancer types. This article provides a systematic comparison across molecular mechanisms, indications, precision, adverse effects, and treatment selection to guide informed clinical decisions.
2026-08-11 05:57:10
Lapatinib is an oral small-molecule tyrosine kinase inhibitor targeting HER2 and EGFR pathways in HER2-positive breast cancer. This article clarifies its therapeutic positioning, clinical applications, and the critical role of HER2 testing in treatment decisions.
2026-08-11 05:22:22
Lapatinib is an oral HER2-targeted anticancer agent. This article covers dosing schedule, food interactions, combination regimens, missed-dose management, drug interactions, and safety monitoring for patients with HER2-positive breast cancer.
2026-08-10 07:50:50
Capivasertib (Truqap) is the first-in-class selective AKT inhibitor approved in combination with fulvestrant for HR-positive, HER2-negative advanced breast cancer harboring PIK3CA/AKT1/PTEN alterations. This guide covers indications, recommended dosing, special populations, warnings, drug interactions, and adverse event management.
2026-08-10 07:34:19
Cemiplimab is a PD-1 immunotherapy drug used for advanced skin cancers and non-small cell lung cancer. As a biologic agent, it requires strict refrigeration at 2°C to 8°C, protection from freezing, light, and agitation to maintain drug stability and efficacy.
